Terms: = Liver cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
19 results:
1. Design, synthesis, and biological evaluation of artemyrianolide H derivatives as potential antihepatoma agents.
Li TZ; Yang XT; Ma WJ; Ma YB; Li FJ; Wang YC; Chen JJ
Bioorg Chem; 2023 Aug; 137():106617. PubMed ID: 37267793
[TBL] [Abstract] [Full Text] [Related]
2. Connecting copper and cancer: from transition metal signalling to metalloplasia.
Ge EJ; Bush AI; Casini A; Cobine PA; Cross JR; DeNicola GM; Dou QP; Franz KJ; Gohil VM; Gupta S; Kaler SG; Lutsenko S; Mittal V; Petris MJ; Polishchuk R; Ralle M; Schilsky ML; Tonks NK; Vahdat LT; Van Aelst L; Xi D; Yuan P; Brady DC; Chang CJ
Nat Rev Cancer; 2022 Feb; 22(2):102-113. PubMed ID: 34764459
[TBL] [Abstract] [Full Text] [Related]
3. The deubiquitinase USP21 stabilizes mek2 to promote tumor growth.
Li W; Cui K; Prochownik EV; Li Y
Cell Death Dis; 2018 May; 9(5):482. PubMed ID: 29706623
[TBL] [Abstract] [Full Text] [Related]
4. [Evaluation of the Occurrence of Surgical Site Infection(SSI)after Hepatectomy in Elderly Patients with Hepatocellular Carcinoma(HCC)].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Kawai K; Inatome J; Murakami K; Naito A; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Kato T; Tamura S; Murata K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1668-1670. PubMed ID: 29394737
[TBL] [Abstract] [Full Text] [Related]
5. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.
Lin B; Zhou X; Lin S; Wang X; Zhang M; Cao B; Dong Y; Yang S; Wang JM; Guo M; Huang J
J Mol Med (Berl); 2017 Nov; 95(11):1237-1249. PubMed ID: 28844099
[TBL] [Abstract] [Full Text] [Related]
6. Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Lin ZY; Chuang WL
Biomed Pharmacother; 2017 Feb; 86():27-31. PubMed ID: 27936391
[TBL] [Abstract] [Full Text] [Related]
7. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract] [Full Text] [Related]
8. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract] [Full Text] [Related]
9. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
[TBL] [Abstract] [Full Text] [Related]
10. Eupolyphaga sinensis walker displays inhibition on hepatocellular carcinoma through regulating cell growth and metastasis signaling.
Zhang Y; Zhan Y; Zhang D; Dai B; Ma W; Qi J; Liu R; He L
Sci Rep; 2014 Jul; 4():5518. PubMed ID: 24980220
[TBL] [Abstract] [Full Text] [Related]
11. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract] [Full Text] [Related]
12. MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells.
Guégan JP; Ezan F; Théret N; Langouët S; Baffet G
Carcinogenesis; 2013 Jan; 34(1):38-47. PubMed ID: 23042098
[TBL] [Abstract] [Full Text] [Related]
13. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract] [Full Text] [Related]
14. Activation of MEK1 or mek2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
[TBL] [Abstract] [Full Text] [Related]
15. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly.
Tsai J; Qiu W; Kohen-Avramoglu R; Adeli K
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):211-8. PubMed ID: 17038630
[TBL] [Abstract] [Full Text] [Related]
16. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway.
Yun C; Cho H; Kim SJ; Lee JH; Park SY; Chan GK; Cho H
Mol Cancer Res; 2004 Mar; 2(3):159-69. PubMed ID: 15037655
[TBL] [Abstract] [Full Text] [Related]
17. [Expression of mitogen-activated protein kinase and its upstream regulated signal in human hepatocellular carcinoma].
Zhu J; Leng X; Dong N; Liu Y; Li G; Du R
Zhonghua Wai Ke Za Zhi; 2002 Jan; 40(1):1-16. PubMed ID: 11955369
[TBL] [Abstract] [Full Text] [Related]
18. Increased MAPK expression and activity in primary human hepatocellular carcinoma.
Schmidt CM; McKillop IH; Cahill PA; Sitzmann JV
Biochem Biophys Res Commun; 1997 Jul; 236(1):54-8. PubMed ID: 9223425
[TBL] [Abstract] [Full Text] [Related]
19. Intracellular copper transport in cultured hepatoma cells.
Freedman JH; Peisach J
Biochem Biophys Res Commun; 1989 Oct; 164(1):134-40. PubMed ID: 2553012
[TBL] [Abstract] [Full Text] [Related]
